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Chapter 1: Overview of General Anesthetics Use in Infants
Abstract: General anesthetics act by either blocking N-methyl-d-aspartate (NMDA) receptors or
over stimulating γ-aminobutyric acid (GABA) receptors.1–3 The actions of these receptors are
responsible for the anesthetized state and are also crucial in the neurological development of
infants.2,4–8 Animal studies, although limited, provide vital information about general
anesthesia’s neurotoxicity its hindrance of neurological development. Exposure to general
anesthesia can severely hinder proper neuronal migration, synaptogenesis, and can drastically
increase neuronal apoptosis in infant animals.9–16 General anesthetics are more neurotoxic to
infant animals in combination compared to individually.10,16,17 Additionally, multiple exposures
to general anesthesia tend to have compounding deleterious effects on neurological development
in infant animals.12 It is likely that repeated exposure and combinational exposure to general
anesthetics are the most detrimental to neurological development. Many retrospective studies on
human infants show a correlation between exposure to general anesthesia and an increased risk
of neurodevelopment disorders.18–25 However, these studies are statistically limited due to
confounding factors. These confounding factors are the reason direct evidence of the neurotoxic
effects of general anesthetics has been so elusive. In vitro human stem cell models provide an
ethical alternative to clinical studies. However, clinical trials are necessary and are the most
promising methods for obtaining direct evidence of the deleterious effects of general anesthesia
on the developing human brain. Different methods used in clinical trials on infants help to
minimalize ethical dilemmas, increase recruitment rates, and maximize safety and expediency.
Specifically, this paper will evaluate the efficacy and safety of different methods used in clinical
trials and will propose how clinical trials can be designed for future studies.
How General Anesthesia Works
According to the 2004 National Hospital Discharge Survey, approximately three million
children in the United States undergo surgical procedures that require general anesthesia.26 This
does not include children that require general anesthesia for nonsurgical purposes such as dental
procedures or imaging studies. A large portion of these children are infants when they are first
exposed to general anesthesia. This fact is concerning considering that many general anesthetics
exhibit neurotoxicity in infant animals (including non-human primates). Furthermore,
retrospective studies demonstrate that children requiring surgery as infants have lower cognitive
performance than children who did not require surgery.20–22,24,25 Unfortunately, many have
criticized this data claiming that these studies could be irrelevant due to confounding factors.
The concern for the long-term neurological effects of general anesthesia on infants
prompted the FDA in 2007 to look into the data concerning general anesthesia’s neurotoxicity.26
The FDA determined that no changes could be made to which general anesthetics are
administered to infants based on current evidence.26,27 However, they urged that more
comprehensive and conclusive clinical studies be conducted promptly to determine which
general anesthetics were neurotoxic to infants or children.26,27 The FDA also recommended that
purely elective surgery be deferred to after 6 months of age at a minimum.26,27 Clinical studies in
infants are crucial considering how long the critical period of neurological development lasts.
General anesthetics have been shown to have the most severe detrimental effects on neurological
development in animals during critical periods known as synaptogenesis.9,10,28 The length of
synaptogenesis in humans lasts from approximately the second trimester of pregnancy to three
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years after birth.21,25,28–30 This is troubling considering many surgical procedures on infants
require general anesthesia.
The two broad classes of anesthesia are local and general. Local anesthetics work by
blocking neural pain signals in a specific site of the body.31 General anesthetics alter the function
of neurons in the central nervous system (CNS) by directly interacting with multiple ion
channels.31 These ion channels control the excitability of neurons by regulating the flow of ions.
An excitatory effect is caused by the neuron depolarizing.31 An inhibitory effect is caused by the
neuron hyperpolarizing.31 The flow of ions (and therefore the polarization of the neuron) is
determined by the anesthetic agent.
The six general anesthetics that are commonly used in pediatric care fall into two
categories: inhalational and intravenous. The inhalational general anesthetics are nitrous oxide,
isoflurane, sevoflurane, and desflurane.31 These are called inhalational anesthetics because they
are administered through a respirator. The intravenous general anesthetics are propofol and
ketamine, which are administered directly into the blood stream.31 General anesthetics act by
either blocking N-methyl-d-aspartate (NMDA) receptors or over-activating γ-aminobutyric acid
(GABA) receptors.1–3 The NMDA receptor is a primary excitatory neurotransmitter receptor in
the CNS.32 The GABA receptor is the most abundant fast inhibitory neurotransmitter receptor in
the CNS.31 The two modes of action for general anesthetics are blocking excitatory signals or
enhancing inhibitory signals.31 Ketamine and nitrous oxide primarily act through blocking
NMDA receptors.2,31 However, they also over-activate GABA receptors but to a lesser degree
than other general anesthetics. Isoflurane, sevoflurane, desflurane, and propofol act primarily by
over-activating GABA receptors.31
The deleterious effects of ethanol on the developing brain are due to ethanol blocking
NMDA receptors and over-activating GABA receptors.33 Ethanol is known to cause severe
neurological developmental disorders in fetuses, such as fetal alcohol syndrome, when ingested
by the mother during pregnancy.33–35 Pregnant women are warned to stay away from alcohol
throughout their entire pregnancy due to the risk of fetal alcohol syndrome. Unfortunately, many
pregnant women or infants cannot be withheld from general anesthesia if surgery is required due
to its necessity for most surgical procedures. Since general anesthesia is essential, it is extremely
important to understand how different general anesthetics affect the developing brain in order to
prevent developmental impairment in infants.
Effects of Blocking NMDA and Over-activating GABA
There are several reasons why blocking NMDA receptors and over-activating GABA
receptors hinder neurological development. The developing brain goes through critical periods
where GABA receptors are stimulated by NMDA receptors.2,7,8 GABA receptors need to be
stimulated in the developing brain in order for immature neurons and oligodendrocytes to mature
properly.36 Stimulation of GABA receptors also strengthens NMDA receptor stimulation and is
vital in the formation of neural networks.4–7 This period of brain development is called
synaptogenesis because new synapses or neuronal connections are being formed.28,37
Connections that are not stimulated are deemed unnecessary by the body and are removed
through a process known as synaptic pruning.38 This process allows poorly stimulated neurons
to go through apoptosis throughout neurodevelopment.4,5 This is one reason why strengthening
neural networks through proper stimulation is so vital to normal neurodevelopment. A study in
mice showed that neurons do not migrate properly to form neural networks when NMDA
receptors are not expressed.39 This same study showed that increasing NMDA receptor
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expression increased neuronal migration and neural network formation.39 The NMDA receptor is
known to be vital to learning and memory.32 Therefore, it is likely that hindered synaptogenesis
or neuronal migration may impair learning and memory.
The proximity of NMDA and GABA receptors allows them to synergistically initiate key
events in neurological developmental. A study in infant mice found that GABA receptor density
was 90 times higher around NMDA receptors than in other parts of the brain.8 These receptors
work in combination to achieve synchronous
synaptic activity.8 Synchronous synaptic activity
occurs when neurons are rhythmically stimulated
with other neurons in the same neural network.8,40
Synchronous synaptic activity is vital to proper
neurological development and neural network
formation.8,41 A study on rat neurons in vitro
found that synchronous synaptic activity led to the
maturation of immature synapses through the
addition of AMPA receptors to synapse containing
the NMDA receptor.40 The addition of AMPA
receptors allows NMDA receptors to be
stimulated.40 AMPA receptors also prevent
afferent connections from forming later on in
neurological development.40
There are serious detrimental
developmental effects when NMDA receptors are
blocked. In vivo studies of infant mice and rats
have shown that the developing brain goes
through excessive neuroapoptosis when NMDA
receptors are blocked for hours at a time.2,42,43
This is in contrast to normal neuroapoptosis that
occurs in the developing brain during critical
periods in order to strengthen neural circuits and
Figure 1: Diagram of a Neuron and its
remove unnecessary connections.28 When the
Structures. Dendritic spines are located on brain undergoes excessive neuroapoptosis
during development, there are life-long
the shafts of the dendrites. The synapse is
detrimental effects. Learning impairments and
formed between the axon of one neuron
48
cognitive disability are common side effects of
and the dendrite(s) of another neuron.
extensive neuroapoptosis during
neurodevelopment.28 This outcome is not surprising considering that an excessive amount of
neurons are dying off leading to gaps in neural networks.
Inhalational Anesthesia and Neurological Development
Antiepileptic drugs have been shown to severely impair cognitive development in infant
44
rats. One large clinical study looked at the frequency of physical birth defects in babies from
epileptic mothers who were prescribed antiepileptic drugs. The study found that exposure to
antiepileptic drugs in utero significantly increased a baby’s risk of being born with physical
abnormalities including major malformations, microcephaly, growth retardation, and hypoplasia
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of the midface and fingers.45 Antiepileptic drugs act on GABA receptors by over-stimulating
them in a manner similar to many general anesthetics.44
Sevoflurane, isoflurane, and desflurane are all inhalational general anesthetics that act by
over-stimulating GABA receptors.31 Sevoflurane, isoflurane, and desflurane have all been shown
to alter dendritic spine density on dendritic shafts in vivo in infant rats after two or more hours
of exposure.46,47 Dendritic spine shafts are main sites of synaptic connections in neural
networks.46,47 The dendrites of a healthy neuron (where the dendritic spines are located) can be
seen in figure 1.48 A primate study demonstrated a 13-fold increase in neuronal apoptosis in
rhesus macaque brain cells in vitro after five hours of exposure to clinical concentrations of
isoflurane compared to controls.15 These results are unfortunate considering that isoflurane is
capable of passing from mother through the placenta into the fetus in humans.49 This indicates
that mothers who receive isoflurane during cesarean sections are inadvertently exposing their
unborn babies to a potentially neurotoxic general anesthetic for the duration of the procedure.
The findings of one in utero study on rats add evidence to the danger of in utero exposure to
isoflurane. The rats in this study were in a stage comparable to the second trimester of pregnancy
in humans.9 The rat mothers were exposed to clinical concentrations of isoflurane for four
hours.9 Babies that were exposed to isoflurane in utero had impaired spatial memory, impaired
learning, and reduced anxiety compared to control rats.9 These symptoms are most likely signs of
improper neurological development.
Studies have found that the use of multiple general anesthetics is actually more
detrimental than using only one anesthetic.10,16,17 Two studies performed on infant rats using
clinically relevant concentrations of nitrous oxide and isoflurane showed that these general
anesthetics used in combination caused severe neuroapoptosis and prevented proper synapse
formation in developmentally vulnerable regions of the brain.10,17 Specifically, these general
anesthetics modified synaptic protein levels. These modifications impaired the function of the
proteins and prevented synaptogenesis.10 This impairment of normal neurological development
and synapse formation could lead to long-term learning impairments and memory deficits. A
study involving in utero guinea pigs showed that isoflurane in combination with nitrous oxide,
compared to isoflurane treatment alone, drastically increased neuronal apoptosis in vulnerable
brain regions as well.16 These studies indicate that inhalational general anesthetics need to be
studied further individually before they can safely be used in combination.
Intravenous Anesthesia and Neurological Development
Propofol is a general anesthetic that acts by over-activating the GABA receptor. Propofol
has been shown to induce neuroapoptosis and cause learning impairments.11,50 An in vivo study
on infant mice found that a quarter of the concentration of propofol needed to induce anesthesia
was sufficient to induce neuronal apoptosis.50 An in vivo study found on infant rats injected with
clinical concentrations of propofol showed signs of neurodegeneration and had learning
impairment compared to control rats.11 These are both expected symptoms from GABA overactivation considering the role of GABA receptors in establishing and strengthening neural
networks.5,7
Ketamine is a general anesthetic that acts by blocking the NMDA receptor. Ketamine is
commonly used in infants during surgical procedures.3 Ketamine has been shown to cause
extensive neuroapoptosis during synaptogenesis.14,43 An in vivo study on infant rats showed that
exposure to ketamine significantly increased neuroapoptosis.43 The infant rats were exposed to
seven doses of ketamine leading to a 28-fold increase in neuroapoptosis compared to controls.43.
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An in vivo study on infant rhesus monkeys showed that exposure to ketamine significantly
increased necrotic and apoptotic neuronal cell death.14 Additionally, the researchers found that
messenger RNA for the NMDA was significantly increased in areas that underwent extensive
cell death.14 Rhesus monkeys that were earlier in development had increased cell death compared
to rhesus monkeys three weeks further in development.14 It is concerning that several animal
studies have shown that concentrations of ketamine, propofol or isoflurane that are
approximately a quarter of that needed for anesthesia still induce neuronal apoptosis in infant
mice.13,50,51
The studies done on primitive mammals provide evidence that the negative effects of
anesthesia on the developing brain are significant. They provoke the need for further research
into the detrimental effects of anesthesia on human infants. However, the clinical significance of
the results of these studies is limited. This is due to the fact that the studies were performed on
primitive mammals. These studies are indicative of neurotoxicity at best and completely
irrelevant at worst. The data from non-human primate studies are more clinically significant.
Non-human primate studies are the closest in vivo model that can translate to humans besides
humans themselves. The agreement in evidence from primitive mammal and non-human primate
studies is sufficient to begin large scale clinical trials on the effects of general anesthetics on
infants.
Current Clinical Research on Infants
Several clinical studies have analyzed the long-term effects of general anesthetics on
infants. They all show that exposure to general anesthetics in infancy increases the risk of
neurodevelopmental disorders.18–25 The studies look at infants that required surgery for various
reasons. They compare the long term neurological development (in areas such as learning,
memory and motor control) to baseline values determined from infants that did not require
surgery. The studies assessed neurological development at varying intervals ranging from two to
ten years after surgery. Collectively, these retrospective studies underscore that infantile
exposure to general anesthesia significantly increases the risk of learning and memory
impairment.18–25 The critics of these studies often point out that confounding factors cannot be
taken into account in these retrospective studies. They claim that this reduces the statistical
significance of the studies. Due to ethical concerns, many critics are skeptical about relying on
evidence from retrospective studies and animal studies as a basis for clinical trials on infants.
The lack of clinical trials leaves doctors lacking accurate information about the safety of
general anesthetics in infants. This ignorance may lead doctors to inadvertently expose babies to
general anesthetics that are neurotoxic. This most likely is already happening as was shown in
the results of one retrospective study. A retrospective study on pregnant women found that
maternal exposure to general anesthesia during the first trimester increased the risk of babies
being born with CNS defects.52 Fortunately, a new in vitro system has been developed using
human stem cells to create a close resemblance to in vivo neurological development.53 This is not
a perfect system because it does not exactly mimic a true in vivo system. However, it is a step
forward in the ethical dilemma that surrounds clinical trials in infants. This in vitro system would
be useful in providing more evidence and data so that clinical trials in infants can proceed. This
stem cell system would be perfect for testing which general anesthetics are neurotoxic during
neurological development.53 This would also be extremely effective at determining methods of
preventing general anesthetics neurotoxic effects.53
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History of Clinical Research on Infants and Children
In the 1930s, the use of drugs on children was widely unregulated.54 Children were often
administered drugs with questionable safety.54 This lead to several adverse events that could
have been avoided. Due to an ingredient used to manufacture the drug elixir of sulfanilamide,
almost 100 children died in the late 1930s.54 Consequentially, an amendment was made to the
Federal Food and Drug Act in 1938 requiring drug ingredients to be labeled honestly and with
documentation of the drug’s safety.54 Sadly, many of the ethical guidelines and regulations
behind clinical trials and requirements for human drug testing have come about due to the
occurrence of severely adverse reactions similar to the example mentioned above.54
In the 1960s, the drug thalidomide was found to cause massive birth defects and
malformations.54 This led to the passing of the Harris–Kefauver Amendment to the Food, Drug
and Cosmetic Act in 1962 which required drugs to be tested on animals before moving to clinical
trials in humans.54 The ethics of clinical trials have often been difficult to discern, leading to an
ever-evolving landscape of ethical guidelines, requirements, and practices.
Informed consent is a perfect example of how greatly ethical guidelines and policies have
changed over the years. The Supreme Court ruled in January 31, 1944 that parents may be free to
become martyrs themselves. But it does not follow they are free, in identical circumstances, to
make martyrs of their children before they have reached the age of full and legal discretion when
they can make that choice for themselves.55 The implications of this ruling were profound. All
nontherapeutic clinical research on minors was considered unlawful even if the parents had
consented. In accordance with the advice from legal experts of the day, this was the stance that
many government agencies took after this 1944 ruling.55
This legal stance was largely met with resistance by practicing physicians. In 1967, The
Royal College of Physicians emphasized the importance that clinical investigations be conducted
with expediency and little regulation.56 Their main recommendation was that doctors should be
free of strict government control so as not to defer clinical trials from occurring.56 They express
their belief that attempting to rigidly control clinical trials would discourage physicians from
conducting such research.56 This would in turn lead to a stagnation in the advancement of
medically relevant clinical knowledge. The conflicting stances of the U.S. government and
medical organizations caused confusion and an ethically difficult situation. The Supreme Court
ruling had little effect on clinical research in humans. Guidelines and regulations were worded in
such a way as to indirectly promote the continuance of nontherapeutic clinical research on
minors. For example, The Royal College of Physicians stated in 1973,
Clinical research investigation of children… which is not of direct benefit to the
patient should be conducted, but only when the procedures entail negligible risk
or discomfort and subject to the provisions of any common and statute law
prevailing at the time.55
This statement does not directly contradict the Supreme Court ruling. However, it does infer that
nontherapeutic clinical research on minors is permissible if it causes negligible harm. The
problem with this guideline is that it is rather subjective. A physician must use their personal
discretion when designing and implementing clinical trials. The lack of clear regulation and
conflicting opinions led to several medical organizations developing their own ethical guidelines
and requirements.
The World Medical Association has developed the Declaration of Helsinki over the last
fifty years. The Declaration of Helsinki is a document that lays out ethical guidelines for how
clinical trials in humans should be conducted.57,58 The document has become increasingly
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inclusive and extensive as ethical issues over clinical trials on humans have arisen.59 The
importance of this document cannot be understated. It has become a standard that is
internationally recognized in the field of bioethics. The Declaration of Helsinki states that the
advancement of medical knowledge is brought about through research which must occasionally
rely on some experimentation involving human patients.57,58 There are several factors that must
be considered when dealing with humans. For example, the Declaration of Helsinki requires that
the well-being of the patient take precedence over the advancement of medical knowledge no
matter how great the benefit.57,58 The foundation of the Declaration of Helsinki was brought
about, like many other guidelines and regulations, as a result of gruesome events. What some
scholars believe to be one of the most important revisions occurred in 1975.59 This revision
required independent committees to review research protocols involving human patients in order
to promote ethical accountability.59
Recently, a group of physicians found that up to 90% of drugs given to neonates were not
used in an authorized manner or were unlicensed.60 This is a frightening statistic because this
would cause neonates to be at a greater risk of drug toxicity. A study conducted in 1998 found
that only 36% of drugs given to children were not used in an approved manner.61 Both these
studies reveal that minors, and especially in neonates, need to be better protected by conducting
further clinical research. Unfortunately, the lack of knowledge on drugs’ effects on children,
infants, and neonates is widespread in medicine. The Physicians’ Desk Reference contains dosing
information based on age, weight, and other criteria. Unfortunately, less than 30% of the entries
in the Physicians’ Desk Reference have statements that the safety and efficacy of the drug in
question has not been determined or dosing information for children, infants, or neonates.54 It is
not ethical to continue to allow these age groups to receive substandard care because of a lack of
knowledge.
This is the main reason the European Medicines Agency met in 2006. They conducted a
workshop that dealt with ways to introduce incentives to researchers in order to promote the
study of drugs safety and efficacy in children, infants, and neonates.62 The Best Pharmaceuticals
for Children Act was passed in 2002 to promote a similar type of incentive in the United States.
The goal of the Best Pharmaceuticals for Children Act was to promote clinical studies of drugs
used off-label in children, infants, and neonates.63 Since the act’s passing in 2002, the Food and
Drug Administration (FDA) and the National Institutes of Health (NIH) have been encouraging
researchers to conduct studies to evaluate the efficacy and safety of the drugs of drugs used offlabel in these vulnerable age groups.63 It is important to understand how drugs are approved for
clinical trials in humans and what kind of guidelines regulate the clinical trials themselves.
The Harris–Kefauver Amendment to the Food, Drug and Cosmetic Act (mentioned
earlier) led to the formation of the investigational new drug (IND) process for testing drug safety
and efficacy in clinical trials.54 The IND created the basic requirements of how new drugs are
tested for safety and efficacy even to this day.54 The IND involves three phases of clinical testing
after the initial preclinical testing. Phase I of the IND involves testing the drug for safety,
methods of metabolism, and its eventual removal from the body of the patient
(pharmacokinetics).54 Phase II involves evaluating the drug for efficacy and proper dosage
according to numerous variables in the patient such as weight and age.54 In phase III, multiple
clinical trials are conducted in order to compare their results.54 One of the most important
considerations during a clinical trial is the risk-to-benefit ratio.
The risk-to-benefit ratio is the amount of risk a patient is exposed to in order to obtain
any kind of beneficial result.54 This ratio takes into account how much risk the patient is being

Page 9
subjected to compared to how much the patient or medical community will benefit.54 Ethically,
physicians should attempt to design trials to achieve low risk and high benefit. Unfortunately, the
nature of the risk-to-benefit ratio makes it rather subjective when implemented.54 Therefore, it is
up to ethical committees and physicians to ensure the risk-to-benefit ratio is accurate and
reasonable.
Ethics of Clinical Research on Infants
A requirement common to all clinical trials (and an especially sensitive topic when
dealing with infants) is informed consent. Problems arise with informed consent because of
subjectivity of updating the patient. Informed consent implies that the patient must be educated
of what clinical experimentation they will be subjected to.64 Additionally, informed consent
implies that the patient must be educated so that they have a thorough understanding of the
risks.64 The education aspect of informed consent presents many problems to the physicians
conducting the clinical research. Education of patients can be time-consuming and counterproductive, leading to poor recruitment rates. This creates an ethical dilemma for the
investigating physician. It is often tempting for the investigating physician to bypass the
educational aspect of informed consent. However, this is a gross violation of the patient’s right to
autonomy. The right of autonomy means the patient should have complete control over his or
her medical care without the coercion of others. The nature of informed consent makes it
especially difficult when conducting clinical research on infants.
The ethical dilemmas of informed consent have caused some critics to suggest that the
informed consent requirement be forgone in incompetent patients. Informed consent is often
time-consuming and can lead to poor recruitment rates. Therefore, it may often seem that
informed consent is counterproductive. Critics of informed consent in the case of incompetent
patients have suggested that ethical committees approve or disapprove clinical trials to take the
burden off of parents and guardians. However, a study on the parents of neonates involved in
clinical trials determined that this would be met with great resistance. Over 80% of the parents in
the study stated that they would be unhappy with not giving informed consent and relying on an
ethical committee.65 Other critics have suggested that the attending physician should decide
whether or not to enroll an incompetent patient in a clinical trial. Yet, the same study mentioned
above found that over 90% of parents said they would be unhappy with the attending physician
making the decision.65 Other studies have also shown that parents prefer to make decisions over
their children in regards to clinical trials.66 However, clinical trials involving infants can achieve
high recruitment rates while still leaving decision-making in the hands of the parents.
Written consent appears to be what harms recruitment rates the most for clinical trials
involving incompetent patients such as infants. It is believed that the anxiety of parents along
with the inability to fully process all the written consent forms leads to poor participation.65,67,68
Morally, it is unacceptable for informed consent to be bypassed altogether.69,70 This kind of
practice would imply that a benefit to society trumps individual rights. However, other methods
of consent can limit anxiety and provide parents with a better understanding of what their infant
will be subjected to. It has been suggested that a progressive approach where parents are
informed throughout the clinical trial will help reduce anxiety and increase recruitment
rates.65,67,68 Additionally, time constraints can be reduced by delegating responsibilities to
different members of ethical committees.68 This streamlining of clinical trial processing would
also assist recruitment rates by giving parents additional time to consider the pros and cons of the
clinical trial. Streamlining clinical trial processing could also decrease the duration of clinical
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trials, leading to an increased rate of medical advancement. Clinical trials in infants must also be
designed in a precautious and safe manner in order to encourage trust and further participation.
Streamlining clinical trials in infants can only be taken so far.
There are several factors that must be taken into careful consideration when designing
clinical trials involving infants. The smaller dosages that are required for infants make them
more susceptible to drug overdose. Even a small percentage of error in dosages can result in
seriously adverse reactions due to the limited maturation of organ systems and low body weight
of infants.71 Additionally, the recommended dosages and infants has to be adjusted in accordance
with their development. For example, after one to two months the dosage of a particular drug
may need to be increased to accommodate organ maturation and weight gain.71 Based on this
understanding, it is important to have extra regulation and precaution when dealing with infants.
This extra care has been criticized by activists who argue that clinical trials in infants need to be
conducted in haste. Unfortunately, this criticism is largely misplaced and probably results from a
lack of understanding concerning the delicate situation of dealing with infants.
What distinguishes neonates from infants is their age. Infants are generally regarded as
babies one month to one year old.71 The term neonate is used to describe a baby just after birth
until they are approximately one month old.71 However, preterm babies are often regarded as
neonates for longer periods of time due to the immaturity of their organ systems.71 Neonates are
more vulnerable than infants due to the inability of their organs to metabolize drugs effectively.71
This is largely because their organs systems are still very immature.62,71 This is also why infants
are considered less vulnerable than neonates. With this information in mind, it is better to recruit
infants and neonates at various stages in development in order to obtain the most reliable
information in regards to drug safety from clinical trials. This particularly important considering
the age of a baby plays an important role in influencing parental consent and emotions.
Interestingly, one study found that parents from a lower socio-demographic background
were more likely to consent to their children being involved in clinical trials.72 Their main
motivation behind participation was the advancement of society.72 This raises an important
question. Should physicians seek to further educate parents from a lower socio-demographic
background or take advantage of their increased participation? Ethically, it is never acceptable to
exploit a parent who is emotionally distressed over his or her child. However, it is possible that
parents from a lower socio-demographic background are simply more altruistic and should be
praised. Either way, physicians must take special care to inform parents from all backgrounds
and to not exploit parental emotions to bolster recruitment.
Discussion
The proper stimulation of NMDA and GABA receptors are vital to neurological
development.2,4–8 These are also the receptors that many general anesthetics act upon.1–3 The
NMDA and GABA receptors play roles in neural network formation, neuronal migration, and
SSA.2,4–8,39,40 These and other neurodevelopmental events are important for learning and
memory.2,4–8 Neurodevelopmental disorders involving learning and memory deficits are expected
if these receptors are blocked or dysregulated. General anesthetics act by blocking NMDA
receptors and over-stimulating GABA receptors.1–3 This means that infants exposed to general
anesthetics can have hindered neurological development during the entire duration of surgery.
Both animal and clinical studies demonstrate that the earlier the exposure to general anesthetics
the more detrimental the effect.14,17,25 General anesthetics most likely impair normal neurological
developmental by blocking stimulation for extended periods of time. NMDA and GABA
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receptors are important in establishing and strengthening neural networks.4–8 A lack of proper
stimulation can lead to neuroapoptosis and subsequent gaps in neural networks.28 These gaps
could likely lead to improper neurological development and negatively impact learning and
memory in the long-term.
Animal models have confirmed that several general anesthetics cause neurodevelopment
disorders by obstructing proper neurological development. Exposure to general anesthesia during
infancy in animals can cause widespread neuroapoptosis and alterations to various structures in
the brain and cause learning and memory impairments.9–16 Even a single exposure to general
anesthesia can drastically increase neuroapoptosis.15 Sevoflurane, isoflurane, and desflurane
altered dendritic spine density after two or more hours of exposure at clinically relevant
concentrations.46,47 This is concerning considering the normal duration of surgical procedures on
infants is longer than two hours. A large number of infants are exposed to detrimental amounts
of potentially neurotoxic general anesthetics considering the typical duration of surgeries. This
follows from the fact that general anesthetics are neurotoxic even after short, single exposures.
Infants that require multiple surgical procedures and exposures to general anesthetics have an
increased risk of neurological developmental disorders. Animal studies show that multiple
exposures to general anesthetics significantly impair neurological development and increase
neuroapoptosis by 28-fold compared to a single exposure.12,43 It is possible that significant
cognitive impairments are only noticeable in infants that have been exposed to general anesthesia
multiple times. Multiple exposures to isoflurane have been shown to severely impair memory
and cause severe learning deficits.12 This suggests that multiple exposures to GABA receptor
agonists can compound the negative effects of general anesthetics on neurological development.
Multiple exposures to general anesthesia causes repeated over-activation of GABA receptors and
blockade of NMDA receptors. This could have compounding effects leading to more severe
neural network degradation by neuroapoptosis.
Unfortunately, many infants that have to go through multiple surgical procedures possess
other developmental disorders that are seen as confounding factors. These confounding factors
limit the statistical significance of the study. However, it is possible that the confounding factors
are distorting the data and leading to an inaccurately low level of reported neurological disorders
due to general anesthesia. In infant rats, multiple exposures to isoflurane drastically increased
cognitive and developmental impairment compared to a single exposure.12 It is unfortunate that
the circumstances that bring a baby into the operating room multiple times for surgery may be
seen as a confounding factor. This could be why it has been difficult to directly link general
anesthesia exposure to cognitive and developmental impairment in human infants.
Several studies have found that the use of multiple general anesthetics is actually more
detrimental than using only one anesthetic.10,16,17 This data indicates that general anesthetics need
to be studied further individually before they can safely be used in combination in infants.
Individual studies would be useful for providing information about why general anesthetics
hinder neurological development and cause extensive neuroapoptosis. The in vitro human stem
cell system is a tool that could prove immensely useful in this regard. While it is not a perfect
replica, the in vitro system does model early neurological development and can ethically be used
in studies.53 This is a more ethical solution than testing various combinations of general
anesthetics on human infants. This system could also be used to determine useful prevention
strategies to combat the neurotoxic effects of general anesthetics on infants. The necessity of
general anesthetics on infants requires that all possible avenues be pursued. Retrospective studies
are also ethically acceptable and useful. The key to retrospective studies is to minimalize
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confounding factors in order to interpret data that is statistically strong. Ethical concerns make
studying the effects of general anesthesia on infants difficult. However, they are still necessary to
prevent further exposure of infants to neurotoxic general anesthetics. Currently, controlled
clinical trials on the effects of general anesthetics on infants are underway. Hopefully, when they
are complete they will provide clinical insight in preventing general anesthesia induced
neurological disorders in infants undergoing surgery. It is likely that these trials will (at the very
least) reveal that repeated exposure and combinational exposure to general anesthetics are the
most detrimental to neurological development.
Clinical trials on infants are controversial and raise several ethical dilemmas. Concerns
over the extent of informed consent and safety of the infants has made extensive ethical
guidelines for clinical trials a necessity. Regulations and ethical guidelines have largely been
shaped by adverse reactions and gruesome events. There has been increasing inclusiveness in
ethical guidelines to ensure that all interest groups are being equally attended to. However,
heavily regulating clinical trials on infants can delay findings and lower recruitment rates. This
raises ethical issues over how informed parents should be and how expediently these trials
should be conducted or approved. There are techniques and methods that can be employed to
maximize participant safety while bolstering recruitment rates and expediency. For example,
written consent can lead to poor recruitment rates and should not be used. Instead, parents should
be informed continually as the clinical trial progresses. Trial design is crucial in this aspect
because it allows medical knowledge to advance at a reasonable rate so that treating neonates
and infants becomes safer and more effective. Without these types of clinical trials, physicians
would not have sufficient evidence to show that they are helping instead of harming an infant.
However, it is best for physicians to err on the side of precaution in all human clinical trials,
especially when dealing with neonates and infants.
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Chapter 2: The Effects of GABA and its Receptor
Introduction
GABA is the predominant inhibitory neurotransmitter in the CNS of mammals.31,73
GABA is an atypical neurotransmitter in regards to its biosynthesis and its effects on other
neurotransmitter concentrations.74 For example, most neurotransmitters rely heavily on recycling
and reuptake after they have produced their effect.74 However, the recycling of GABA is not as
important as synthesis of new GABA.74 The receptor for GABA has two main subtypes, GABAA
and GABAB. The GABAA and GABAB receptors are ubiquitous inhibitory neurotransmitter
receptors in the CNS, found on almost all cortical neurons.31,73 The NMDA and AMPA receptors
work in conjunction with GABA receptors and will be briefly discussed in this chapter.
However, the main focus of this chapter will be on the GABAA receptor due to its important role
in neurodevelopment.
GABA Synthesis and Catabolism
The precursor to GABA is glutamic acid (also known as glutamate when negatively
charged).75 The new synthesis of GABA requires neurons to have a supply of glutamate which
they are not reliant on de novo glutamate synthesis.75 This requires neurons to import glutamate
or glutamine, which can be converted by neurons to glutamate.75 Not surprisingly, neurons that
release GABA express transporters for the import of glutamate and glutamine.76,77
Glutamine synthetase is the enzyme responsible for converting glutamate to glutamine.75
Glutamine synthetase is expressed in astrocytes which subsequently release this newly converted
glutamine to be taken up by GABA releasing neurons.75 The conversion of glutamate to
glutamine helps to detoxify ammonia and recycle neurotransmitters for inhibitory and excitatory
neurotransmission.75 In GABA releasing neurons, glutaminase type I (GLS1) is the enzyme
responsible for the conversion of glutamine back to glutamate.75 The enzyme glutamic acid
decarboxylase (GAD) is responsible for the conversion of glutamate to GABA.75 After GABA
has been synthesized, it is moved to synaptic vesicles to be released into the synapse.74
Expectantly, inhibiting GAD reduces the amount of GABA containing vesicles released into the
synapse.78
Neurons are capable of undergoing glucose metabolism including the citric acid cycle.
Glutamate can be synthesized from the citric acid cycle intermediate α-ketoglutarate.75 However,
this has minimal contribution to glutamate pools in GABA releasing neurons.75 Blockade of both
GABA synthesis and degradation reduces the amount of GABA-containing vesicles that are
released into the synapse.79 Interestingly, blockade of GABA reuptake by GABA transporters
does not affect the amount of GABA-containing vesicles that are released.79 Taken together, this
suggests that GABA reuptake is more important for its ability to enter the citric acid cycle than
to be reused as a neurotransmitter.
The excitatory amino acid transporter-3 (EAAT3) is expressed at the terminals of neurons
that release GABA. The EAAT3 allows these neurons to reuse glutamate by importing it back
into the cell for GABA synthesis. Sodium coupled neutral amino acid transporter 1 and 2, termed
SNAT1 and SNAT2 respectively, allow neurons to import glutamine. Astrocytes express
EAAT2 which has a similar function to EAAT3.
GABA is broken down by the enzyme GABA transaminase (GABA-T).75 GABA-T
removes and amino group converting GABA into succinc semialdehyde (SSA).75 SAA is further
degraded into succinate by the enzyme SSA dehydrogenase.75 Succinate can then enter the citric
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acid cycle. This breakdown of GABA allows neurons to compensate for the citric acid cycle
intermediate α-ketoglutarate that is used to synthesize GABA. An excellent image representing
the metabolism of GABA can be seen in figure 2.75
GABAA and Other
Receptors
As one of the earliest
synapse systems to form, the
importance of the GABAA
receptor and its substrate to
neurodevelopment cannot be
stressed enough.80 Overactivating GABAA receptors
results in widespread
inhibition throughout the brain
that can be detrimental during
critical periods such as
synaptogenesis. GABAA
receptors must be properly
stimulated in order for
immature or undifferentiated
neurons to mature
appropriately.36 The NMDA
receptor is also greatly
affected by the activation of
the GABAA receptor. Since the
Figure 2: GABA Metabolism. The import of substrates
NMDA receptor is one the
needed for GABA synthesis (top left), the transport of
most widespread excitatory
GABA to the synapse (bottom middle), and the reuptake
receptors and GABAA is one of
of GABA for further use (top right) are all shown in this
the
most widespread inhibitor
figure. Relevant abbreviations are mentioned in the text
receptors, they are intrinsically
above.75
related in the formation of
2,7,8
neural networks.
Neural networks cannot properly form without inhibition and stimulation
induced by the GABAA and NMDA receptor respectively.4–8 Synaptogenesis also relies on the
actions of both receptors. Unsurprisingly, there are gaps in neural networks when the NMDA and
GABAA receptors are inhibited or over-activated respectively.28 This is due to the fact that
during synaptogenesis neurons that are not stimulated or “used” get removed by undergoing
apoptosis.4,5 This has concept has been termed synaptic pruning and is most likely the main
neurodevelopmental process affected by general anesthetics.38
Other receptors are also important in neurodevelopment including the AMPA receptor.
The GABAA and NMDA receptors are located in close proximity to each other. However,
AMPA receptors are located essentially right on top of NMDA receptors and affect their signal
processing.40 In order for neurons to fire in coherent patterns, termed synchronous synaptic
activity, synapses containing the NMDA receptor must have AMPA receptors added to them.8,40
The AMPA receptors allow NMDA receptors to become activated by their ligands.40 After
AMPA receptors are activated, GABA and NMDA receptors must work cooperatively to achieve
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synchronous synaptic activity.40 This developmental process helps to strengthen necessary
connections within neural networks and remove unnecessary connections.8,40
Effects of Receptors
The GABAA receptor activity is largely controlled by cation-chloride cotransporters
(CCC). Binding of GABA to the GABAA receptor can result in propagation or inhibition of a
signal. What determines the fate of the signal is the concentration of chloride ions, which can
pass through the receptor
upon GABA binding. CCCs
are responsible for
controlling cellular
concentrations of sodium
and potassium. A specific
type of CCC, the
sodium/potassium/chloride
cotransporter (NKCC1)
increases the chloride
concentration inside the
cell.81 NKCC1 imports
sodium and potassium with
their concentration gradient
to force the chloride ions
against their concentration
gradient.81 The binding of
Figure 3: Cation-Chloride Transporters. This is a figure
GABA to the GABAA
depicting the GABAA receptor and how the flow of ions is
receptor causes an efflux of
affected by its absence (a, c) and upon binding (b, d).81
chloride ions resulting in
depolarization.81
Depolarization results in a propagation of a signal from one neuron onto others. In contrast, the
CCC potassium/chloride cotransporter 2 (KCC2) decreases the chloride concentration inside the
cell.81 The KCC2 uses potassium to remove chloride ions from inside the cell.81 The binding of
GABA in this scenario causes an influx of chloride ions resulting in hyperpolarization.81
Hyperpolarization results in the reduction of a signal and essentially inhibits signal transduction
from one neuron to the next. This is how CCCs help to regulate GABAA receptor mediated
inhibition.81 An excellent figure depicting these interactions can be seen in figure 3.81
The NMDA receptor is essentially the opposite of the GABAA receptor, which is an anion
channel. The NMDA receptor is a cation channel that controls the flow of sodium and calcium
ions into the cell.82–84 The main ligands for the NMDA receptor are glycine and glutamate. 82–84
Upon binding to glycine and glutamate, the NMDA receptor becomes depolarized resulting in
signal propagation.82–84 The binding of glycine and glutamate causes the NMDA receptor to open
allowing the influx of positively charged ions including sodium but especially calcium.82–84 This
high permeability to calcium makes the NMDA receptor rather unique.82–84
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Another novel feature of the N
NMDA
MDA receptor is that it is blocked by magnesium ions
82–84
preventing depolarization.
When NMDA receptors are stimulated for too long of a period,
the high amount of calcium influx can affect cellular viability.82–84 This does not typically
happen when general anesthetics are
administered. Instead, general
anesthetics that are NMDA antagonists,
such as isoflurane and nitrous oxide,
result in an increase
se in NMDA receptor
83
expression. The increased density of
the NMDA receptor results in greater
stimulation upon neurotransmitter
release from the pre-synaptic
synaptic neuron.83
This can result in an influx of calcium
that is virtually identical to excessive
stimulation and can ultimately induce
apoptosis.85
The AMPA receptor (like
like the
GABA and NMDA receptors) is an
ionotropic receptor, meaning it forms an
ion pore within the membrane.83 The
AMPA receptor allows the influx of
sodium, potassium, and in some
Figure 4: The Effects of Normal
ormal and Excessive
instances calcium.83 The AMPA recep
receptor
Activation
of
the
NMDA
Receptor
eceptor. The levels
is similar to the NMDA receptor in that it
of calcium influx resulting from normal and
is an excitatory receptor and is one of the
excessive activation of the NMDA receptor (b).
most abundant types of receptors in the
83
The binding of glutamate and glycine for
CNS. The AMPA and NMDA receptor
excessive periods of time can induce calciumcalcium
both have a tetrameric
meric structure that is
85
depicted in figure 4. The exact roles of
mediated neurotoxicity. The theorized tetrameric
AMPA receptors have not been
structure of the NMDA
MDA receptor embedded
completely elucidated.83 However, it is
within the membrane is also accurately depicted
known that AMPA receptors are
in part b. The far left image of part a shows the
extremely fast excitatory receptors that
NMDA under normal conditions. The middle and
serve a similar, although quicker, role as
right images show the NMDA receptor under
NMDA receptors in regards to signa
signal
rapid (tetanic) and excessive stimulation
propagation.83
respectively.
ively. Rapid and excessive stimulation
The GABAA receptor is a
results in the removal of magnesium ions that
heteropentameric receptor that spans the
block the pore of the NMDA receptor. Lastly,
membrane four times while the GABAB
excessive stimulation of the NMDA receptor
receptor is a heterodimeric receptor that
73
results in large calcium influx that promotes cell
spans the membrane seven times. The
GABAA receptor is an ionotropic
death through the activation of apoptotic
receptor, meaning it permits ion
on influx
cascades. The AMPA receptor has a very similar
when bound to its ligand, specifically
structure to the NMDA receptor.85
73
chloride or bicarbonate ions. The
GABAB receptor is a G-protein
protein coupled
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receptor.73 When a ligand binds to
the GABAB receptor it activates a
G-protein
protein that goes on to turn on an
effector.73 An excellent figure
showing the differences between
the GABAA and GABAB receptor
can be seen in figure 5.73
As mentioned above, the
GABAA receptor is made up of five
protein subunits to form an ion
channel that is selectively
permeable to chloride and
bicarbonate ions.73 Each subunit of
the receptor contains four
hydrophobic alpha-helices that
span the membrane.73 The C and N
termini are located on the
extracellular surface of the cell
membrane.73 However, there is a large
intracellular loop that contains
phosphorylation sites that are important
in regulating the receptor.73

Figure 5: The Structure of the GABAA and
GABAB receptor. This figure depicts the GABAA
and GABAB receptor embedded in the plasma
membrane along with their relative structures and
modes of activation (voltage change in part a and
secondary messenger in part b).73

Discussion
Commonly used general
anesthetics in pediatric practice all affect the GABAA to some extent. Therefore, it is the
arguably the most important receptor to discuss when evaluating how general anesthetics may
affect
neurodevelopm
Table 1
ent. However,
nesthetics on Ligand-gated Ion Channels.
Effects of General Anesthetics
the importance
a. Volatile anesthetics
GABAA
AMPA
NMDA
of the AMPA
+++
---/0
Isoflurane
and NMDA
receptors in
+++
-/0
--Nitrous oxide
neurodevelopm
+++
unknown
unknown ent is significant
Sevoflurane
as well.
b. Intravenous anesthetics
GABAA
AMPA
NMDA
Additionally,
the AMPA and
+/0
0
--Ketamine
NMDA
receptors are
+++
-/0
-/0
Propofol
Table 1: +++ represents activation and --- represents inhibition of the receptor at clinically
relevant concentrations. +/0 represents a small activation while -/0
/0 represents a small
inhibition of the receptor at clinically relevant concentrations. 0 represents no effect at any
concentration.83
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affected by activation of the GABAA receptors especially during early development. Due to the
complex interactions of these receptors, it is important to understand how general anesthetics
affect all these receptors to fully elucidate the negative effects of general anesthetics on
neurodevelopment. Evidence from animal and in vitro studies suggest that general anesthetics
affect neural network formation causing potentially life-long negative effects on learning and
memory. This is most likely due to the widespread inhibition caused by general anesthetics
resulting in increased apoptosis.
A table displaying the current scientific consensus, which is supported by a multitude of
studies, on how five commonly used general anesthetics in pediatric care act on important and
widely distributed receptors in the CNS can be seen in table 1.83 The AMPA, NMDA, and
GABAA receptors are all affected by general anesthetics although every general anesthetic does
not affect each receptor. Isoflurane inhibits AMPA receptors to the greatest extent followed by
nitrous oxide and propofol. Isoflurane, nitrous oxide, propofol, and sevoflurane activate GABAA
receptors to the greatest extent while ketamine only slightly activates. Nitrous oxide and
ketamine inhibit NMDA receptors to the greatest extent while isoflurane and propofol only
slightly inhibit.
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Chapter 3: Proposing a Clinical Trial in Infants
Introduction
In 2007, the FDA investigated the long-term neurological effects of general anesthesia on
infants due to concerns over neurotoxicity.26 They concluded that clinical studies should be
conducted expediently to determine conclusively which general anesthetics should and should
not be administered to infants 26. Infants are especially vulnerable to neurotoxins due to the
extensive amount of neurodevelopment taking place during the first years of life. One critical
period of neurological development, known as synaptogenesis, is severely hindered by general
anesthetics. The human brain undergoes synaptogenesis from approximately the second trimester
of pregnancy to three years after birth.21,25,28 Experiments on infant animals have shown that
general anesthetics negatively influence neurological development.9,10,28 There is a desperate
need for more information about general anesthetic safety considering the vulnerability of infants
and their frequency of general anesthesia exposure due to non-elective surgery.
The developing brain must be properly stimulated in order for neurological development
to take place. Without proper stimulation, neurons within neural networks will undergo apoptosis
in an effort to remove unneeded or unused connections.28 General anesthetics alter the
stimulation of two vital receptors, NMDA and GABA.2,4–8 NMDA and GABA receptors are
crucial in the formation of neural networks, stimulating neuronal migration, establishing firing
patterns necessary for coherent thought processes.2,4–8,39,40 Early formation of neural networks
and neuronal migration have long-term effects on memory and learning.2,4–8 Additionally, while
it is not clear why some general anesthetics are less detrimental to neurological development, our
study aims to elucidate more information on the relative safety of general anesthetics. Animal
studies have demonstrated that early exposure to general anesthesia during neurodevelopment
has more pronounced negative effects.14,17,25
How General Anesthetics Induces Apoptosis
A strong signal for a cell to undergo apoptosis is caspase-3 activation.86–88 Caspase-3 is
activated through the actions of cytochrome c.86–88 Cytochrome c is released from mitochondria
due to an increase in permeability of the mitochondrial membrane.86–88 One signal that increases
mitochondrial membrane permeability is large influxes of calcium into mitochondria.86–88
Several in vitro and in vivo studies have shown that exposure to general anesthetics induce
neuroapoptosis through caspase-3 activation.89–95 Two in vitro studies on mice and human
neurons showed that exposure to clinically relevant levels of isoflurane increased levels of
cytochrome c.89,96
There are several proposed mechanisms that could explain why isoflurane causes the
release of cytochrome c leading to caspase-3 activation. Some studies have indicated that
isoflurane can directly interact with the mitochondrial permeability transition pore (mPTP)
causing it to open.97,98 mPTP opening allows cytochrome c to be released subsequently inducing
neuroapoptosis.86–88 Magnesium and propofol are both mPTP blockers.97,98 Two studies showed
that magnesium and propofol are effective at blocking isoflurane-induced mPTP opening,
reducing caspase-3 activation, and inhibiting neuroapoptosis in vitro in human neurons and in
vivo in mice.97,98 This is one example of how a GABA agonist can increase calcium
concentrations inside the cell induce neuroapoptosis. The NMDA antagonist ketamine also
affects mitochondrial membrane permeability causing cytochrome c to be released.99 This has
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Figure 6: Results of Neuron Exposure to
Ketamine. A. Neurons exposed to ketamine
had increased mitochondrial membrane
permeability. B. Not relevant to the topic
being discussed. C. DAPI staining was used
to visualize nuclear DNA (shown in blue)
while mitochondria were tagged with a
green fluorescence protein (shown in green).
D. Cytochrome C localization was analyzed
using an immunofluorescence staining
(shown in red). The merged images clearly
depict that ketamine treatment results in a
cytochrome C exiting the mitochondria
(where they are present in normal cells) and
instead localizing in the cytosol where they
can induce apoptosis.99

led many experts to believe that many general
anesthetics induce apoptosis in this fashion.99
The results of this experiment are shown and
explained in figure 6.99 Isoflurane has other
potential mechanisms by which it can induce
apoptosis such as altering calcium.
Calcium plays a major role in cell
signaling and the inositol 1, 4, 5-triphosphate
(IP3) receptor is a major route for mobilizing
calcium stores in almost all cell types.100 The
IP3 receptor is located on the endoplasmic
reticulum (ER) that regulates calcium
release.100 Due to the close proximity of IP3
receptors and mitochondria, over-activation of
the IP3 receptor causes calcium depletion in the
ER and calcium uptake in mitochondria.100,101
Therefore, over-activation of the IP3 receptor
can induce caspase-3 activation and cellular
apoptosis by increasing mitochondrial
membrane permeability.86,87,100,101 In vitro
studies have shown that isoflurane increases
intracellular calcium levels in rat neurons.102,103
One study on rat neurons showed that
isoflurane at clinically relevant concentrations
interacts with the IP3 receptor.103 This
interaction causes calcium dysregulation that
induces neuroapoptosis.103 Moreover,
isoflurane did not induce apoptosis in neurons
that lacked IP3 receptors at any concentration
or length of exposure.103 Two in vitro studies
have shown that compounds that block IP3
receptor activity inhibit isoflurane-induced
apoptosis.103,104 Isoflurane also induces
caspase-3 activation which is capable of
triggering additional calcium dysregulation.89–
95
Caspase-3 activation can cleave IP3
receptors causing permanent calcium leakage
from the ER.104 Figure 7 shows the different
pathways that can lead to an imbalance of
calcium and induce cellular apoptosis.51
Inhibition of the NMDA receptor
causes neurons containing this receptor to
compensate by increasing NMDA receptor
expression.27 Upon relief of inhibition, these
neurons typically have too much calcium
influx due to activation of an excessive amount
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of NMDA receptors.
This can lead to apoptosis through cytochrome c release from the mitochondria. This
appears to be the main mechanism by which general anesthetics that are NMDA antagonists
induce apoptosis.27 However, as demonstrated by isoflurane, there may be other unknown
mechanisms by which NMDA receptor antagonists or GABA receptor agonists that contribute to
general anesthetic neurotoxicity. For example, ketamine is a NMDA antagonist that also causes
cytochrome c release.
Animal Models and Clinical Trials
There is mounting evidence
that general anesthetics used in
pediatric care are damaging to the
developing brain. General
anesthetics act through NMDA
antagonism and/or GABA
stimulation have been show to
induce apoptosis in the developing
rat brain.105 Studies on infant mice
and rats have shown that NMDA
blockade or GABA over-activation
for hours at a time increases the rate
of neuroapoptosis in the developing
brain.9–16 Several anesthetics have
Figure 7: Calcium Dysregulation and Apoptosis.
been shown to induce apoptosis in a
The Bcl-2 protein controls calcium homeostasis by
dose dependent manner including:
interacting with the IP3 receptor. Excessive release of
propofol, isoflurane, and ketamine.9–
calcium from ER through the IP3 receptor increases
16,27,106
Normally, the brain
mitochondrial membrane permeability. This allows
undergoes periods of intense
cytochrome c to be released and activate caspase-3.
neuroapoptosis during development
Caspase-3 induces apoptosis and cleaves the IP3
in order to remove extraneous
receptor leading to permanent calcium leak from the
connections and strengthen neural
ER.51
circuits. 28 The increase in
neuroapoptosis during development can lead to life-long learning disabilities.28 This is most
likely due to the loss of connections that are necessary for the proper functioning of important
neuronal circuits. Dendritic spines are also drastically altered in structure upon exposure to
general anesthetics.46,47 Dendritic spines are necessary for proper synapse formation and
function.46,47 The loss of dendritic spines can lead to problems with learning and memory dud to
gaps in neural networks. 46,47
A group of researchers looked at how isoflurane affected dendritic spines. They found
that exposure to isoflurane caused a reduction in dendritic spines.47 However, the addition of the
proteases plasmin and tissue plasminogen activator (tPA) were both shown to reduce the
isoflurane-induced reduction of dendritic spines.47 tPA is the protease that converts plasminogen
to plasmin.47 Plasmin and tPA, through their effects on plasmin levels, affect the concentration of
a ligand called pro-brain derived neurotrophic factor (pro-BDNF).47 Pro-BDNF is converted to
mature BDNF by plasmin.47 Pro-BDNF is capable of binding to a receptor that induces
apoptosis, the p75NTR receptor.47 Isoflurane reduces the levels of tPA released by decreasing
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neuronal activity through over-activating GABA receptors. tPA is released in response to
neuronal activity.47 Studies using animal models have shown that BDNF is important for
promoting neuronal growth, survival, and differentiation.107 This is one potential mechanism by
which isoflurane may promote neuroapoptosis. A figure depicting the results of the study can be
seen in figure 8.47
There is evidence to suggest that a
combination of general anesthetics,
particularly those that act primarily on
different receptors, are more detrimental
to neurodevelopment.10,16,17,105 A study
looked at the effects of clinically relevant
exposure of rats to midazolam, nitrous
oxide, and isoflurane for six hours.105
Nitrous oxide acts as an NMDA
antagonist, causing inhibition. However,
isoflurane acts as a GABA agonist,
causing inhibition. Nitrous oxide acts as a
GABA agonist as well (albeit to a slightly
lesser degree). Wide-spread apoptosis in
the developing brain of these rats
suggests that exposure to a combination
of general anesthetics that act primarily
on different receptors is more detrimental
Figure 8: Dendritic Spine Density. Slides of
than exposure to a single anesthetic
neonatal primary neurons in vitro using drebrin
agent.105 This is an agreement with
studies in other animal models.
immunofluorescence microscopy (part A and B).
Furthermore, this study showed that the
The primary neurons were exposed to isoflurane
infant rats that were exposed had spatial
for 4 hours at a concentration of 1.4% (clinically
learning and memory deficits as
relevant) and subsequently stained 2 hours later
adolescents and adults compared to
for debrin and doublecortin. Isoflurane exposure
controls.105 Besides a negative
reduced levels of drebrin (shown in green)
combinatorial effect, there is evidence
expression in the primary neurons. Yet,
that multiple exposures to general
doublecortin (shown in red) expression levels
anesthetics is much more detrimental
were not affected. Plasmin and tPA were
than a single exposure. One study
administered to the neurons and significantly
showed that apoptosis in neurons was
reduced the loss of dendritic spines induced by
elicited in infant rats after repeated
isoflurane. The neurons were also stained with
exposure to ketamine over a nine hour
DAPI (shown in blue) to highlight nuclear DNA.
period.106 This study is just one of many
studies that demonstrates that repeated
Areas of overlap appear as combinations of the
exposure to general anesthetics is more
colors mentioned. The quantification of the data
47
detrimental than a single exposure.12,43,106
can be seen in part C.
Several studies using infant
rodents and primates have revealed that the greatest damage to neurodevelopment induced by
general anesthetics is during periods of peak synaptogenesis.9–16,108 The infant brain undergoes
periods of synaptogenesis from the second trimester of pregnancy to around three years of
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age.21,25,28–30 Virtually all of the brain undergoes increased neuronal growth throughout the
period of synaptogenesis with the growth of various areas, such as the temporal and frontal lobe,
peaking at different points.27 This could contribute to the difficulty in evaluating the detrimental
of effects of general anesthesia in a clinical setting on infants and should be taken into
consideration.
One of the main concerns many experts have with the current research done in animal
models is clinical translation.37 The timing of development and exact clinically relevant
concentrations of general anesthetics are difficult to standardize and extrapolate when working
between species.37 However, this concern does not change the fact that the most current research
at a minimum warrants that clinical trials in infants be conducted. It is time for an answer
concerning whether general anesthetics are safe for the infant brain.
There are several studies that have tracked and directly assessed infant development
following surgical repair. However, none of these studies recorded the concentration or duration
of general anesthesia exposure. Additionally, many of the studies did not address confounding
factors, making their results irrelevant to the current topic.107 Yet, there are studies that have
utilized the digitization of medical records to track the development of large cohorts of children
exposed to general anesthesia in retrospective and epidemiological studies.
Many retrospective studies on human infants show a correlation between exposure to
general anesthesia and an increased risk of neurodevelopment disorders especially in learning
and memory.18–25 Learning and memory deficits are consistent with data from animal models.105
Animal studies on the effects of general anesthetics on neurodevelopment have shown that the
hippocampus is the area of the brain that is most severely affected.27 The hippocampus is one of
the most important areas of the brain in regards to learning and memory formation. Also, the
NMDA receptor is known to be vital to learning and memory.32 The agreement of clinical trials,
extensive studies using animal models, and in vitro experiments is strong evidence that general
anesthetics affect learning and memory development in some form or fashion.
Unfortunately, the types of retrospective and epidemiological studies performed thus far
are statistically limited due to confounding factors. Unfortunately, a correlation is usually not
enough to cause changes in clinical practice. Causation is the gold standard that must be
achieved before the scientific community can come to a consensus that eventually leads to
changes in clinical practice. Regardless, the results of these studies are still concerning and
should be taken very seriously considering their possible implications. For example, one study
that evaluated children exposed to general anesthesia before age three found that they had
reduced language and cognitive development even after one exposure.109 Several studies have
also found that young children exposed to anesthesia have chronic behavioral irregularities that
last up to one month after exposure.18,25,109–112 This occurs in up to 50% of young children that
receive general anesthesia.18,25,109–112 The most common behavioral abnormalities include
irritability, anxiety, and insomnia.25,112,113 Unsurprisingly, the younger the child is at the time of
exposure results in more pronounced behavioral irregularities.25,112,113
Interestingly, regional anesthetics are being evaluated for their safety in clinical practice
in order to reduce or eliminate the need for general anesthetics during procedures. Regional
anesthetics are similar to local anesthetics except that they block pain signals over relatively
large portions of the body. While local anesthesia is typically administered to the tissue
surrounding the desired site, regional anesthesia is administered to bundles of nerves or even the
spinal cord to deliver broad nerve blockade over a relatively large portion of the body.
Dexmedetomidine is a regional anesthetic being evaluated due to its minimal side-effects.114 It
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can be used in conjunction with general anesthetics to reduce dosage requirements.114 Other
regional anesthetics are being looked at for similar reasons.114 One study evaluated the outcomes
of over 5,000 births to determine the effects of giving birth under regional or general anesthesia.
The study concluded that mother’s that received regional anesthesia during childbirth had
children with fewer instances of learning disabilities than those who received general
anesthesia.110 However, the process of proving the safety of these regional anesthetics takes time
and the results of these studies are far off. Therefore, it is important to evaluate the safety of a
variety of drugs used to achieve anesthesia in case the safety of some proves to be questionable
and are no longer used in practice. Withholding anesthesia altogether is not an ethical option due
to known detrimental effects of severe stress or pain on neurodevelopment.107 Severe stress or
pain drastically increases neuroapoptosis, stress hormones, pain tolerance, and instances of
aberrant behavior.107
Human Stem Cell Model Design
This trial will employ the use of an in vitro human stem cell model made up of neural
stem cells (NSCs) to study neurodevelopment. As mentioned above, general anesthetics have
been shown to be most detrimental during times of intense synaptogenesis. The developing brain
goes through intense synaptogenesis until the age of two.115 There has been great success in
experiments using neural stem cell models to evaluate the effects of various drugs on the
developing brain.53 NSCs can be acquired from infant and adult nervous tissue.53 The ability to
derive these cells from adults makes the acquisition and use of these cells less controversial and
more universally accepted. Embryonic mouse fibroblasts will be used as feeder cells to ensure
the NSCs remain viable in vitro.53 A transmission electron microscope will be employed to
evaluate the level of synaptogenesis and neural network formation throughout the duration of the
experiment.53 The transmission electron microscope will also be used to evaluate the
ultrastructure of the NSCs to visualize any abnormalities in organelles or cell structure upon
exposure to general anesthetics agents.53
The employment of an in vitro human stem cell model has several unique advantages. It
is an ethical manner to obtain experimental data that has high translation to in vivo human
neurodevelopment. The use of NSCs ensures that a virtually unlimited supply of cells can be
maintained for exhaustive research opportunities. Additionally, the in vitro nature of the model
allows tight control of experimental parameters, such as concentration of general anesthetic
exposure. By avoiding animal sacrifice, NSCs can be evaluated more directly and frequently in a
cost-efficient manner. This model has the potential to elucidate the molecular action of
individual general anesthetics due to the several advantages mentioned above.
In order to properly set up the neural stem cell model, a chemically defined a media is
needed. The protocol described in Bai and Bosnjak will be used to ensure that iPSCs differentiate
properly into mature neurons.113 This process is described in more detail in figure 9.116 The
media helps to mimic the in vivo conditions of the brain causing neural stem cells to differentiate
into several neuronal lineages including neurons, oligodendrocytes, and astrocytes.113 This model
has been effective in producing functional synapses that mimic in vivo synapses.117 This model
has proven it to be quite efficient in causing neurons to undergo differentiation. One study
achieved 90% differentiation of cells into NSCs using this model.99
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The NSCs will be exposed to
sevoflurane, propofol, ketamine,
isoflurane, and nitrous oxide, the
most commonly used general
anesthetics currently used in infants.
The dosage to which NSCs will be
exposed to will vary between
anesthetic agents. However, all
agents will be evaluated at .5, 1, 2,
and 4 times the clinically
recommended concentration.
Experiments will be conducted at a
duration of 1, 2, 4, or 8 hours of
general anesthetic exposure. The
frequency of exposure to each
general anesthetic will be 1, 2, or 3
times. Controls will not be exposed
to the general anesthetic agent.
However, they will be exposed to all
the same conditions with only the
carrier gas used to deliver the
individual anesthetic agents.
A variety of assays will be
used in conjunction with the
transmission electron microscope to
obtain a better idea of how
Figure 9: Neural Stem Cell Model. This figure depicts
general anesthetics may cause
how human embryonic stem cells (hESCs) can be induced
neurotoxicity. Cellular
to differentiate into various types of neurons in a four step
proliferation will be evaluated
process that is translatable to iPSCs. The fours step process
using bromodeoxyuridine (a
thymidine analog that gets
causes hESCs to differentiate into embryoid body
incorporated into newly
formations, neural rosette cells, neural stem cells, and
formed DNA) and Ki67 (a
various types of neurons in that order (part A). Stem cell
non-histone, nuclear protein
markers are shown in pink and green in part b and c to
that is not expressed in
indicate differentiation is starting to occur. In parts d and e,
dormant cells).53 Cell viability
nuclear DNA is shown in blue and a neuroepithelial marker
will be measured using an
is shown in green (only part e), indicating the hESCs had
LDH and MTT assay. A 3(4,5-dimethyithiazol-2-yl)-2,5- developed into embryoid bodies. In part g, a biomarker
specific to neural stem cells is shown in red, indicating the
diphenyl-tetrazolium bromide
embryoid bodies have differentiated into neural stem cells.
(MTT) dye is used to measure
In part C, the cells have fully differentiated into neurons and
mitochondrial function and
118
are expressing two biomarkers specific to neurons, β-tubulin
cell viability. The MTT dye
III shown in green (part b) and MAP2 which is also shown
is degraded by mitochondrial
dehydrogenase activity,
in green (part c). Additionally, the neurons expressed two
producing a colored
biomarkers specific to synapses, synapsin-1 shown in red
(part d) and Homer 1 shown in green (part e).116
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product.118 This concentration of this colored product will then be quantified using a
spectrophotometer. Lactate dehydrogenase (LDH) is an enzyme that can pass through the
cellular membrane if it is damaged.118 The concentration of LDH in culture will be quantified
using an LDH assay to determine the amount of cells that are damaged or nonviable.118 Realtime PCR will also be employed to elucidate which genes are over- or under-expressed upon
general anesthetic exposure. RNA will be extracted from experimental and control cells. This
RNA will be reverse transcribed and amplified using PCR. The resulting cDNA will be run
through a database and quantified to determine levels of gene expression.118
It is believed that the primary mechanism of neurotoxicity by general anesthetics is
increased apoptosis.118 DNA fragmentation can be visualized using terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate in situ nick end labeling (TUNEL) staining.
DNA fragmentation is indicative of cellular apoptosis.118 The level of DNA fragmentation will
be recorded using a confocal microscopy to quantify the amount of cells going through
apoptosis.118 A caspase-3 colorimetric assay will also be used to quantify the number of cells
going through apoptosis.118
This model has been used to effectively evaluate the neurotoxic effects of ketamine and
isoflurane individually. Both studies found that prolonged exposure to either general anesthetic
increased neuroglia cell proliferation and neuronal apoptosis.99,116 Isoflurane and ketamine both
caused apoptosis by increasing cytochrome c and reactive oxygen species levels.99,116 While the
concentration and duration of general anesthetic exposure were outside of clinical relevance,
these studies do show that a neural stem cell model is an ideal method for evaluating how
general anesthetics influence cellular processes inducing apoptosis in vitro.
Clinical Trial Design
Participants will be selected from a pool of infants that are two years of age or younger
that are requiring surgery for issues unrelated to neurodevelopment. The age was decided to
correlate with the critical neurodevelopmental period of synaptogenesis. Synaptogenesis occurs
in the human brain from the time of birth to approximately three years of age.37 During surgery,
the general anesthetic(s) used will be recorded along with the concentration and duration of
exposure. Other drugs used and any complications during surgery will also be noted. Participants
will receive free-of-charge anesthesia upon commitment to assessments of cognitive and
behavioral development every other year for eight years. Assessments every other year will
allow a greater range of development to be assessed for a more cost-effective approach. The
assessments will be based on the outcome of the neural stem cell experiment as well as previous
clinical trial conclusions.
The assessments employed will be the Wechsler Abbreviated Scale of Intelligence
(WASI) and NEuroPSYchological Assessment, second edition (NEPSY II). WASI will be used
to evaluate global cognitive function by determining global IQ and verbal skills.119 NEPSY II
will be used to evaluate specific cognitive functions.119 A behavioral assessment will be
conducted by providing the Child Behavior Checklist ages 2-10 to the parents.119 The sibling of
participants will perform identical assessments with the same professional at the same age as
their sibling. Age-specific instruments will be used during the assessments to reduce statistical
variability and potential error.26 This will not be an issue since siblings will perform identical
assessments at the same age as their sibling that was exposed to general anesthesia. Siblingpairing has been shown to be an effective method for reducing confounding factors because
inter-sibling differences are minimal in comparison to random selection.26 We hypothesize that
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depending on the age of exposure different areas of the brain will be affected, producing a slight
variation of symptoms. This is based on the fact that synaptogenesis peaks at different times in
different areas of the brain.27 However, we also hypothesize that learning and memory will be
affected the most, which would agree with current data from animal model studies.27
Discussion
There is a drastic need for more information about the safety of using general anesthetics
in infants. Too many infants are being exposed to potentially neurotoxic agents that could have
devastating effects on neurodevelopment. Unfortunately, while the evidence suggests that
general anesthetics could be neurotoxic, the lack of consensus by the medical community has
prevented any changes in clinical practice from occurring.
The critical periods of brain development are important in the synaptogenesis in the
formation of neural networks. However, during this critical time period, neuronal stem cell
proliferation, neuronal migration, and the formation of axons and dendrites also occurs within
this time.113,120,121 Therefore, general anesthetics have the potential to affect several
neurodevelopmental processes.113,120,121 These neurodevelopmental processes can be stimulated
in neural stem cells, providing an ideal model for evaluating general anesthetic neurotoxicity in
vitro.113 An additional benefit of using neural stem cells is that they can replicate the phenotype
of a patient with an heritable disease.113 Assuming the in vitro neural stem cell model is effective
in the trial proposed, it could capture the interest of researchers and lead the utilization of stem
cells in future studies. This stem cell model would be a useful method for carefully and
repeatedly evaluating how genetic factors influence pathology. One of the only downsides of this
technology is that the results of studies cannot be directly translated to a true in vivo system.
However, this is a fault that is necessary due to the nature of in vitro studies. The current study
would greatly benefit if stem cell technologies were capable of culturing many types of neurons
to gather to more accurately mimic the conditions of an in vivo brain. As new technologies
emerge and interest grows, future studies could utilize this type of stem cell model to produce
more conclusive and translatable data.
This study is unique and provides valuable contributions to the field in several ways.
First, this will be one of a few studies to evaluate the neurotoxicity of general anesthetics using
the in vitro neural stem cell model. Second, this is the first clinical trial to evaluate general in
anesthetics in vivo and in vitro simultaneously. Third, this is currently one of the first studies
directly assessing neurodevelopmental outcomes of children exposed to general anesthetics as
infants using sibling-paired controls. Lastly, no other study has evaluated the number of general
anesthetics we will be evaluating using the in vitro neural stem cell model.
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